217 related articles for article (PubMed ID: 27127222)
21. Tumor imaging and therapy using radiolabeled somatostatin analogues.
de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP
Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476
[TBL] [Abstract][Full Text] [Related]
22. DOTA-D-Tyr(1)-octreotate: a somatostatin analogue for labeling with metal and halogen radionuclides for cancer imaging and therapy.
Li WP; Lewis JS; Kim J; Bugaj JE; Johnson MA; Erion JL; Anderson CJ
Bioconjug Chem; 2002; 13(4):721-8. PubMed ID: 12121126
[TBL] [Abstract][Full Text] [Related]
23. Characterization of
Willekens SMA; Joosten L; Boerman OC; Brom M; Gotthardt M
Sci Rep; 2018 Feb; 8(1):2948. PubMed ID: 29440684
[TBL] [Abstract][Full Text] [Related]
24. Radiosynthesis and Preclinical Evaluation of
Maschauer S; Heilmann M; Wängler C; Schirrmacher R; Prante O
Bioconjug Chem; 2016 Nov; 27(11):2707-2714. PubMed ID: 27715017
[TBL] [Abstract][Full Text] [Related]
25. Radiolabeled new somatostatin analogs conjugated to DOMA chelator used as targeted tumor imaging agent: synthesis and radiobiological evaluation.
De K; Banerjee I; Misra M
Amino Acids; 2015 Jun; 47(6):1135-53. PubMed ID: 25743164
[TBL] [Abstract][Full Text] [Related]
26. A Cyanine-Bridged Somatostatin Hybrid Probe for Multimodal SSTR2 Imaging in Vitro and in Vivo: Synthesis and Evaluation.
Heing-Becker I; Grötzinger C; Beindorff N; Prasad S; Erdmann S; Exner S; Haag R; Licha K
Chembiochem; 2021 Apr; 22(7):1307-1315. PubMed ID: 33238069
[TBL] [Abstract][Full Text] [Related]
27. The addition of DTPA to [177Lu-DOTA0,Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivity.
Breeman WA; van der Wansem K; Bernard BF; van Gameren A; Erion JL; Visser TJ; Krenning EP; de Jong M
Eur J Nucl Med Mol Imaging; 2003 Feb; 30(2):312-5. PubMed ID: 12552352
[TBL] [Abstract][Full Text] [Related]
28. Biodistribution and dosimetry of 177Lu-labeled [DOTA0,Tyr3]octreotate in male nude mice with human small cell lung cancer.
Schmitt A; Bernhardt P; Nilsson O; Ahlman H; Kölby L; Schmitt J; Forssel-Aronsson E
Cancer Biother Radiopharm; 2003 Aug; 18(4):593-9. PubMed ID: 14503955
[TBL] [Abstract][Full Text] [Related]
29. Fundamental study of radiogallium-labeled aspartic acid peptides introducing octreotate derivatives.
Ishizaki A; Mishiro K; Shiba K; Hanaoka H; Kinuya S; Odani A; Ogawa K
Ann Nucl Med; 2019 Apr; 33(4):244-251. PubMed ID: 30604401
[TBL] [Abstract][Full Text] [Related]
30. Clinical Translation of a Click-Labeled 18F-Octreotate Radioligand for Imaging Neuroendocrine Tumors.
Dubash SR; Keat N; Mapelli P; Twyman F; Carroll L; Kozlowski K; Al-Nahhas A; Saleem A; Huiban M; Janisch R; Frilling A; Sharma R; Aboagye EO
J Nucl Med; 2016 Aug; 57(8):1207-13. PubMed ID: 27173162
[TBL] [Abstract][Full Text] [Related]
31. The Design and Preclinical Evaluation of a Single-Label Bimodal Nanobody Tracer for Image-Guided Surgery.
Debie P; Declerck NB; van Willigen D; Huygen CM; De Sloovere B; Mateusiak L; Bridoux J; Puttemans J; Devoogdt N; van Leeuwen FWB; Hernot S
Biomolecules; 2021 Feb; 11(3):. PubMed ID: 33652977
[TBL] [Abstract][Full Text] [Related]
32. SSTR-Mediated Imaging in Breast Cancer: Is There a Role for Radiolabeled Somatostatin Receptor Antagonists?
Dalm SU; Haeck J; Doeswijk GN; de Blois E; de Jong M; van Deurzen CHM
J Nucl Med; 2017 Oct; 58(10):1609-1614. PubMed ID: 28450563
[TBL] [Abstract][Full Text] [Related]
33. Tecnetium-99m as alternative to produce somatostatin-labeled derivatives: comparative biodistribution evaluation with 111In-DTPA-octreotide.
Melo IB; Ueda LT; Araujo EB; Muramoto E; Barboz MF; Mengatti J; Buchpiguel CA; Silva CP
Cell Mol Biol (Noisy-le-grand); 2010 May; 56(2):31-6. PubMed ID: 20525456
[TBL] [Abstract][Full Text] [Related]
34. The glucose-dependent insulinotropic polypeptide receptor: a novel target for neuroendocrine tumor imaging—first preclinical studies.
Gourni E; Waser B; Clerc P; Fourmy D; Reubi JC; Maecke HR
J Nucl Med; 2014 Jun; 55(6):976-82. PubMed ID: 24744444
[TBL] [Abstract][Full Text] [Related]
35. 110mIn-DTPA-D-Phe1-octreotide for imaging of neuroendocrine tumors with PET.
Lubberink M; Tolmachev V; Widström C; Bruskin A; Lundqvist H; Westlin JE
J Nucl Med; 2002 Oct; 43(10):1391-7. PubMed ID: 12368379
[TBL] [Abstract][Full Text] [Related]
36. PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature.
Johnbeck CB; Knigge U; Kjær A
Future Oncol; 2014 Nov; 10(14):2259-77. PubMed ID: 25471038
[TBL] [Abstract][Full Text] [Related]
37. Radio-guided surgery in neuroendocrine tumors.
Gulec SA; Baum R
J Surg Oncol; 2007 Sep; 96(4):309-15. PubMed ID: 17726664
[TBL] [Abstract][Full Text] [Related]
38.
Liu F; Zhu H; Yu J; Han X; Xie Q; Liu T; Xia C; Li N; Yang Z
Tumour Biol; 2017 Jun; 39(6):1010428317705519. PubMed ID: 28618966
[TBL] [Abstract][Full Text] [Related]
39. PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel 18F-labelled, carbohydrated analogue of octreotide.
Wester HJ; Schottelius M; Scheidhauer K; Meisetschläger G; Herz M; Rau FC; Reubi JC; Schwaiger M
Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):117-22. PubMed ID: 12483418
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]